Somatostatin Analogs - Somavert Prior Authorization Criteria – Medicare Part D
Medicare Utilization Management Policy
Version Date: January 1, 2025
Prior Authorization Criteria for Approval
Initial Evaluation
Somavert will be approved when BOTH of the following are met:
-
The patient has a diagnosis of acromegaly AND ONE of the following:
-
There is evidence of a claim that the patient is currently being treated with the requested medication within the past 90 days
OR -
The prescriber states the patient is currently being treated with the requested medication AND provided clinical justification to support that the patient is at risk if therapy is changed
OR -
BOTH of the following:
-
ONE of the following:
- The patient is not a candidate for surgical resection or pituitary radiation therapy
OR - The requested medication is for adjunctive therapy with pituitary radiation therapy
OR - The patient had an inadequate response to surgery or pituitary radiation therapy as indicated by serum IGF-1 levels that are above the reference range
AND
- The patient is not a candidate for surgical resection or pituitary radiation therapy
-
ONE of the following:
- The patient has tried and had an inadequate response to octreotide or Somatuline Depot (lanreotide)
OR - The patient has an intolerance or hypersensitivity to octreotide or Somatuline Depot (lanreotide)
OR - The patient has an FDA labeled contraindication to octreotide or Somatuline Depot (lanreotide)
AND
- The patient has tried and had an inadequate response to octreotide or Somatuline Depot (lanreotide)
-
-
-
The requested dose is within FDA labeled dosing for the requested indication
Length of Approval: 6 months
Renewal Evaluation
Somavert will be approved when ALL of the following are met:
- The patient has been previously approved for the requested medication through the plan’s Prior Authorization criteria
AND - The patient has a diagnosis of acromegaly
AND - The patient has had clinical benefit with the requested medication
AND - The requested dose is within FDA labeled dosing for the requested indication
Length of Approval: 12 months